Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.54 |
| ▸ | BRPF1 | P55201 | 5/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238251 | 0.96 | KCNA5 (0.53) | KCNA5BRPF1KCNA3CYP2D6HRH3 | |
| SCHEMBL1238357 | 0.92 | BRPF1 (0.54) | KCNA5BRPF1CYP2D6HRH3CA12 | |
| SCHEMBL12080777 | 0.86 | KCNA5 (0.54) | KCNA5BRPF1KCNA3CYP2D6HRH3 | |
| SCHEMBL1237022 | 0.85 | KCNA5 (0.59) | KCNA5BRPF1KCNA3CYP2D6HRH3 | |
| SCHEMBL1238359 | 0.84 | KCNA5 (0.53) | KCNA5BRPF1KCNA3CYP2D6HRH3 | |
| SCHEMBL1236983 | 0.83 | KCNA5 (0.51) | KCNA5BRPF1CYP2D6HRH3CA12 | |
| SCHEMBL19231464 | 0.81 | BRPF1 (0.45) | KCNA5BRPF1KCNA3CYP2D6HRH3 | |
| SCHEMBL15809257 | 0.81 | PDE3B (0.59) | KCNA5BRPF1KDM4EMEN1KMT2A | |
| SCHEMBL30086904 | 0.81 | PDE3B (0.59) | KCNA5BRPF1KDM4EMEN1KMT2A | |
| SCHEMBL15986369 | 0.81 | KCNA5 (0.49) | KCNA5BRPF1CYP2D6HRH3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARMA CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARCACEUTICAL CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-8822453-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2746272-A1 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-20120225866-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2467364-A2 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011021726-A2 | NITROGEN-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | KCNA5 9/4885BRPF1 2093/4885KCNA3 28/4885 |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | KCNA5 9/4885BRPF1 2093/4885KCNA3 28/4885 |
| US-20120225866-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | KCNA5 9/4885BRPF1 2093/4885KCNA3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.